298
Nephrotoxicity of Co-Administration of Tacrolimus and Teicoplanin in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Poster Abstracts
Longhorn Hall E (Exhibit Level 1) (Gaylord Texan)
Takehiko Mori
,
Division of Hematology, Keio University School of Medicine, Tokyo, Japan
Takayuki Shimizu
,
Division of Hematology, Keio University School of Medicine, Tokyo, Japan
Jun Kato, MD
,
Division of Hematology, Keio University School of Medicine, Tokyo, Japan
Sumiko Kohashi, MD
,
Division of Hematology, Keio University School of Medicine, Tokyo, Japan
Yuya Koda
,
Division of Hematology, Keio University School of Medicine, Tokyo, Japan
Masuho Saburi, MD
,
Division of Hematology, Keio University School of Medicine, Tokyo, Japan
Shinichiro Okamoto, MD, PhD
,
Division of Hematology, Keio University School of Medicine, Tokyo, Japan
Backgrounds: Both tacrolimus and glycopeptide antibiotics are nephrotoxic, and are frequently co-administered after hematopoietic stem cell transplantation (HSCT). The aim of this study is to evaluate the nephrotoxicity of co-administration of tacrolimus and glycopeptide antibiotic, teicoplanin, in HSCT recipients.
Patients and methods: Sixty-seven patients who received intravenous tacrolimus and teicoplanin concomitantly for more than four days after allogeneic HSCT were retrospectively examined. Therapeutic drug monitoring (TDM) was performed in all patients both for tacrolimus and teicoplanin.
Results: The median duration of the co-administration of tacrolimus and teicoplanin was 11 days (range: 4-40). The mean serum creatinine (sCr) level tended to be elevated after the co-administration of tacrolimus and teicoplanin (from 0.69±0.26 to 0.75±0.30 mg/dL; P= 0.08); however, a two-fold or greater increase of sCr was observed only in 2 (3.0%) patients. Increased sCr was tolerable and reversible.
Conclusion: These results suggest that the nephrotoxicity of the co-administration of tacrolimus and teicoplanin is minimal after allogeneic HSCT if the TDM of each drug is properly applied.
Disclosures:
Nothing To Disclose
